High density lipoproteins (HDLs) are commonly known for their anti-atherogenic properties that include functions such as the promotion of cholesterol efflux and reverse cholesterol transport, as well as antioxidant and anti-inflammatory activities. However, because of some chronic inflammatory diseases, such as type 2 diabetes mellitus (T2DM), significant changes occur in HDLs in terms of both structure and composition. These alterations lead to the loss of HDLs’ physiological functions, to transformation into dysfunctional lipoproteins, and to increased risk of cardiovascular disease (CVD). In this review, we describe the main HDL structural/functional alterations observed in T2DM and the molecular mechanisms involved in these T2DM-derived modifications. Finally, the main available therapeutic interventions targeting HDL in diabetes are discussed.
Dysfunctional high-density lipoproteins in type 2 diabetes mellitus: Molecular mechanisms and therapeutic implications / Bonilha, I.; Zimetti, F.; Zanotti, I.; Papotti, B.; Sposito, A. C.. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:11(2021), p. 2233.2233. [10.3390/jcm10112233]
Dysfunctional high-density lipoproteins in type 2 diabetes mellitus: Molecular mechanisms and therapeutic implications
Zimetti F.;Zanotti I.;Papotti B.;
2021-01-01
Abstract
High density lipoproteins (HDLs) are commonly known for their anti-atherogenic properties that include functions such as the promotion of cholesterol efflux and reverse cholesterol transport, as well as antioxidant and anti-inflammatory activities. However, because of some chronic inflammatory diseases, such as type 2 diabetes mellitus (T2DM), significant changes occur in HDLs in terms of both structure and composition. These alterations lead to the loss of HDLs’ physiological functions, to transformation into dysfunctional lipoproteins, and to increased risk of cardiovascular disease (CVD). In this review, we describe the main HDL structural/functional alterations observed in T2DM and the molecular mechanisms involved in these T2DM-derived modifications. Finally, the main available therapeutic interventions targeting HDL in diabetes are discussed.File | Dimensione | Formato | |
---|---|---|---|
jcm-10-02233-v2.pdf
accesso aperto
Tipologia:
Versione (PDF) editoriale
Licenza:
Creative commons
Dimensione
962.84 kB
Formato
Adobe PDF
|
962.84 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.